HeartBeam completes enrollment of 486‑patient ACS study in Indonesia
HeartBeam Inc. finished enrolling 486 patients in its HEADSTART‑ACS study, which evaluates the diagnostic accuracy of its 3‑D ECG system for acute coronary syndrome. The study was conducted with Indonesia’s National Cardiovascular Center and data analysis is underway, with results slated for presentation in 2027. The enrollment puts the company’s total heart‑attack detection study experience above 600 patients, ahead of its U.S. pivotal trial planned for Q1 2027.
Why it matters
The company says the expanded clinical data will support the upcoming U.S. pivotal study and help de‑risk regulatory approval for heart‑attack detection. Investors will watch the 2027 results for indications of the device’s performance and market potential.
Key facts
- 1486 patients were enrolled in the HEADSTART‑ACS study. stocktitan.net
- 2The study was conducted in collaboration with Indonesia’s National Cardiovascular Center. stocktitan.net
- 3Data analysis is ongoing and results are expected for presentation at a cardiology conference in 2027. stocktitan.net
- 4HeartBeam now has clinical experience with more than 600 patients across the HEADSTART‑ACS and ALIGN‑ACS studies. stocktitan.net
- 5The U.S. pivotal study is planned for Q1 2027. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.